Last reviewed · How we verify

Bupivacaine heavy and Morphine

Post Graduate Institute of Medical Education and Research, Chandigarh · FDA-approved active Small molecule

Bupivacaine heavy (hyperbaric) provides local anesthesia via sodium channel blockade, while morphine provides opioid analgesia via mu-receptor agonism, used together for intrathecal spinal anesthesia and analgesia.

Bupivacaine heavy (hyperbaric) provides local anesthesia via sodium channel blockade, while morphine provides opioid analgesia via mu-receptor agonism, used together for intrathecal spinal anesthesia and analgesia. Used for Intrathecal spinal anesthesia and analgesia for surgical procedures, Postoperative pain management.

At a glance

Generic nameBupivacaine heavy and Morphine
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh
Drug classLocal anesthetic + opioid combination
TargetVoltage-gated sodium channels (bupivacaine); mu-opioid receptor (morphine)
ModalitySmall molecule
Therapeutic areaAnesthesiology / Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine heavy is a long-acting local anesthetic that blocks sodium channels in nerve fibers, preventing action potential propagation and producing reversible sensory and motor blockade. Morphine is a mu-opioid receptor agonist that enhances analgesia and provides prolonged postoperative pain relief when administered intrathecally. The combination leverages synergistic effects for comprehensive perioperative anesthesia and analgesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: